Eijkman Institute’s Merger, the End of Merah Putih Vaccine?

Ilustrasi Vaksin Merah Putih
Summary

The development of the Merah Putih vaccine by the Eijkman Molecular Biology Research Center (PRBM) stalled as the institute merged into the National Research and Innovation Agency (BRIN). Amin Soebandrio, who led this institution when it was still Eijkman Institute for Molecular Biology (LBM), said that the emergency use of authorization (EUA) for a recombinant protein-based COVID-19 vaccine could not be obtained by mid-2022, a setback from the previously set target.

Amin said the delay was due to the integration process of Eijkman into BRIN. When the transition process began, the budget that the Ministry of Research and Technology previously approved had not been disbursed. "If only LBM Eijkman were given the opportunity, facilities, and budget like when we were assigned in 2020, the vaccine should have been completed sooner," Amin said before the House of Representatives (DPR) on January 17, 2022.

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.